Antibodies Against Epstein-Barr Virus Glycoprotein gp42 for the Diagnosis of Nasopharyngeal Carcinoma.
Antibodies Against Epstein-Barr Virus Glycoprotein gp42 for the Diagnosis of Nasopharyngeal Carcinoma.
复制标题
DOI：
10.7754/clin.lab.2015.150723
复制
发表时间：
2016
影响因子：
0.7
通讯作者：
Rui-chen Li;Yong Du;Qiuyao Zeng;L. Tang;Hua Zhang;Yan Li;Wan-li Liu;Qian Zhong;M. Zeng;Xiaoming Huang
中科院分区：
文献类型：
--
作者：
Rui-chen Li;Yong Du;Qiuyao Zeng;L. Tang;Hua Zhang;Yan Li;Wan-li Liu;Qian Zhong;M. Zeng;Xiaoming Huang
背景检测EB病毒(EBV)免疫球蛋白A(IgA)抗体对鼻咽癌的早期诊断具有重要意义。EBV糖蛋白GP42已被证明在与B细胞膜融合中发挥重要作用。本研究旨在探讨血清中抗EBV糖蛋白GP42抗体能否作为鼻咽癌诊断的新指标。方法用重组杆状病毒系统表达的EBV糖蛋白GP42，采用酶联免疫吸附试验(EL ISA)检测血清中抗GP42抗体。采集406例鼻咽癌患者(鼻咽癌患者208例，健康对照组198例)的血样。用受试者工作特征(ROC)计算诊断准确率。结果ROC曲线显示，IgAGP42EL ISA诊断鼻咽癌的敏感性为76.4%，特异性为78.3%，曲线下面积为0.856(95%CI，0.82~0.891)。此外，在病毒衣壳抗原(VCA)阴性的鼻咽癌患者中，GP42保持了诊断能力(87.5%、64.1%和0.844[95%CI，0.776-0.912])。联合检测可提高诊断能力(89.9%、94.4%和0.973[95%CI，0.959~0.9871])。结论EBV糖蛋白复合体GP42可作为鼻咽癌诊断的一种新的生物标志物，提高对VCA阴性鼻咽癌患者的识别率。
BACKGROUND Assessment of immunoglobulin A (IgA) antibody responses to Epstein-Barr virus (EBV) antigen is important for the early diagnosis of nasopharyngeal carcinoma (NPC). EBV glycoprotein gp42 has been shown to play an essential role in membrane fusion with B cells. The aim of the present study was to assess whether the antibodies to EBV glycoprotein gp42 in serum could be a novel marker for diagnosis of NPC. METHODS EBV glycoprotein gp42 expressed in the recombinant baculovirus system was used in an enzyme-linked immunosorbent assay (ELISA) to detect antibodies to gp42 in serum. The blood samples were obtained from 406 participants (n = 208 patients with NPC and 198 healthy controls). Receiver operating characteristics (ROC) was used to calculate diagnostic accuracy. RESULTS The ROC curves showed that IgA-gp42 ELISA had a sensitivity of 76.4%, specificity of 78.3% and an area under the curve (AUC) of 0.856 (95% CI, 0.82 - 0.891) to diagnose NPC. Furthermore, gp42 maintained diag- nostic capacity in NPC patients who were IgA-viral capsid antigen (VCA) negative (87.5%, 64.1% and 0.844 [95% CI, 0.776 - 0.912]). Combining gp42 and VCA improved the diagnostic capacity compared with the individual tests (89.9%, 94.4% and 0.973 [95% CI, 0.959 - 0.9871). CONCLUSIONS The EBV glycoprotein complex gp42 acts as a novel biomarker for diagnosis of NPC and improves identification of patients with VCA-negative NPC.